Clinical Trial Update: A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS [Phase 1]

View source ↗

Summary

Phase I trial of OXi4503 for relapsed and refractory acute myeloid leukemia and myelodysplastic syndromes was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• OXi4503

Snippet

Sponsor: University of Florida | Conditions: Leukemia, Myelogenous, Acute, Myelodysplastic Syndromes | Phase 1 | Status: TERMINATED